Takeda to sell another non-core portfolio for $260 million to Cheplapharm
pharmafile | September 8, 2020 | News story | Manufacturing and Production, Sales and Marketing | Cheplapharm, Takeda, pharma
Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an upfront payment of $562 million.
The portfolio of products, sold primarily in Europe and Canada, include therapies in the anti-inflammatory and cardiovascular/metabolic spaces which generated $260 million in sales for Takeda throughout 2019’s fiscal year.
The Japanese pharma firm is jettisoning the products as they no longer fit within its five key therapeutic areas of gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.
“Today’s announcement allows Takeda to continue to be patient-focused as we streamline and optimise our portfolio according to our global long-term strategy,” remarked Costa Saroukos, Chief Financial Officer at Takeda. “While the trusted products included in the sale address key patient needs in these countries, they are outside of our core business areas of focus. We are confident that Cheplapharm is the right partner to ensure patients continue to have access to these products.”
The decision follows the sale last month of the company’s Consumer Healthcare Company to global investment firm Blackstone for around £2.3 billion, the sale of a non-core over-the-counter (OTC) portfolio of drugs sold in the Asia Pacific to Celltrion for $278 million in June, and the sale in April of another OTC portfolio in Europe to Orifarm for up to $670 million. The moves represent Takeda’s attempts to balance the books following its mammoth acquisition of Shire in 2018 for $62 billion.
Matt Fellows
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
